Key Points
- John Fesko sold 1,688 shares of Natera on April 27 at an average price of $204.10 for $344,520.80, reducing his stake by 0.89% to 187,511 shares; the sale was disclosed to the SEC and executed under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding on vested awards.
- The sale is part of a recent pattern of insider dispositions (including Fesko trades in February and March), which—while largely routine under 10b5‑1 plans—can create perceived supply/overhang and contributed to near‑term selling ahead of the company’s May 7 earnings print.
- Natera recently beat quarterly expectations with $0.35 EPS (vs. -$0.46 est.) and $665.5M revenue (vs. $600.7M est.), and analysts remain broadly positive with an average rating of "Moderate Buy" and a $253.47 target, supported by heavy institutional ownership.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 1,688 shares of Natera stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $204.10, for a total value of $344,520.80. Following the transaction, the insider owned 187,511 shares of the company's stock, valued at $38,270,995.10. This represents a 0.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Fesko also recently made the following trade(s):
- On Tuesday, March 10th, John Fesko sold 707 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $144,319.91.
- On Tuesday, February 3rd, John Fesko sold 3,594 shares of Natera stock. The stock was sold at an average price of $231.02, for a total value of $830,285.88.
Natera Price Performance
Shares of Natera stock opened at $194.75 on Thursday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The company has a market capitalization of $27.71 billion, a P/E ratio of -127.29 and a beta of 1.68. The business has a 50 day moving average price of $202.22 and a 200 day moving average price of $213.80.
Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. During the same period in the previous year, the firm posted ($0.41) EPS. As a group, research analysts expect that Natera, Inc. will post -1.71 EPS for the current fiscal year.
Institutional Trading of Natera
Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Reflection Asset Management purchased a new stake in Natera in the 4th quarter worth approximately $29,000. Palladiem LLC purchased a new stake in Natera in the 4th quarter worth approximately $31,000. Horizon Investments LLC purchased a new stake in Natera in the 3rd quarter worth approximately $32,000. Bank of Jackson Hole Trust grew its stake in shares of Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock valued at $37,000 after buying an additional 83 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Natera during the 4th quarter valued at $39,000. 99.90% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on NTRA shares. Wall Street Zen upgraded Natera from a "hold" rating to a "buy" rating in a research report on Saturday, April 18th. Citigroup initiated coverage on shares of Natera in a research note on Wednesday, January 7th. They issued a "buy" rating and a $300.00 target price for the company. Zacks Research raised shares of Natera from a "strong sell" rating to a "hold" rating in a research note on Thursday, January 1st. Wells Fargo & Company lifted their target price on shares of Natera from $205.00 to $215.00 and gave the stock an "equal weight" rating in a research note on Friday, February 27th. Finally, Morgan Stanley lowered their target price on shares of Natera from $265.00 to $250.00 and set an "overweight" rating for the company in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $253.47.
Read Our Latest Research Report on Natera
Key Natera News
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Recent operating results and analyst interest provide a bullish backdrop: Natera reported an upside quarter (Feb. 26) with revenue and EPS above consensus, and multiple firms maintain buy/overweight views and price targets above the current price — a structural tailwind if execution continues.
- Positive Sentiment: Large institutional buying in recent quarters (e.g., Coatue, Wellington added sizable positions) indicates continued conviction from some allocators, which can limit downside and support recovery after volatility. Quiver Quant: Natera shares slide
- Neutral Sentiment: Multiple insider sales have been announced (CEO, CFO and other executives) but were executed under pre‑arranged Rule 10b5‑1 plans and primarily to cover tax withholdings on vested awards — routine from a governance perspective but can be interpreted differently by the market. See one SEC disclosure for the CFO sale on Apr. 29. CFO Form 4 (Apr 29)
- Negative Sentiment: Near-term de‑risking ahead of the May 7 earnings print has pressured the stock — several market summaries point to position‑sizing into the report, which increases short‑term volatility and drove selling momentum. Quiver Quant: Natera shares slide
- Negative Sentiment: Analyst caution and supply/overhang concerns: a recent downgrade to hold (circulated in April) and a string of Form 144/insider sale disclosures have kept investors focused on potential selling pressure; investors may also be scrutinizing management’s 2026 revenue/gross‑margin guidance as a tougher setup after strong prior growth. Yahoo Finance: Should You Be Bullish on Natera?
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
